

Ola Landgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10853251/publications.pdf>

Version: 2024-02-01

218
papers

19,861
citations

14614

66
h-index

11581

135
g-index

220
all docs

220
docs citations

220
times ranked

15061
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014, 15, e538-e548.	5.1	3,343
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016, 17, e328-e346.	5.1	1,866
3	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. <i>Blood</i> , 2009, 113, 5412-5417.	0.6	904
4	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
5	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	1.7	356
6	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
7	B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2009, 360, 659-667.	13.9	322
8	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010, 116, 5501-5506.	0.6	308
9	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2020, 396, 186-197.	6.3	299
10	Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2010.	3.8	294
11	Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. <i>Blood</i> , 2006, 107, 904-906.	0.6	280
12	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. <i>Journal of Clinical Oncology</i> , 2007, 25, 1993-1999.	0.8	275
13	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	3.4	266
14	Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. <i>Hepatology</i> , 2009, 49, 116-123.	3.6	253
15	Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. <i>Haematologica</i> , 2014, 99, 392-398.	1.7	249
16	Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. <i>International Journal of Cancer</i> , 2009, 125, 398-405.	2.3	221
17	Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. <i>British Journal of Haematology</i> , 2009, 144, 86-94.	1.2	220
18	Smoldering multiple myeloma. <i>Blood</i> , 2015, 125, 3069-3075.	0.6	211

#	ARTICLE	IF	CITATIONS
19	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019, 291, 5-13.	3.6	209
20	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	0.6	204
21	Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. <i>Blood</i> , 2008, 111, 3388-3394.	0.6	195
22	A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. <i>Haematologica</i> , 2017, 102, 910-921.	1.7	187
23	Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. <i>British Journal of Haematology</i> , 2007, 139, 809-819.	1.2	185
24	Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. <i>Journal of Clinical Oncology</i> , 2011, 29, 2514-2520.	0.8	183
25	Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case-Control Study in Scandinavia. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1321-1330.	3.0	179
26	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). <i>Blood</i> , 2011, 118, 4086-4092.	0.6	173
27	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 830-834.	0.8	165
28	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , 2011, 117, 5573-5581.	0.6	161
29	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. <i>Blood</i> , 2008, 112, 3052-3056.	0.6	143
30	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1468-1473.	1.4	142
31	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. <i>Blood</i> , 2009, 113, 6386-6391.	0.6	137
32	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. <i>Blood</i> , 2010, 116, 1056-1059.	0.6	137
33	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	0.6	133
34	Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. <i>International Journal of Cancer</i> , 2006, 118, 3095-3098.	2.3	125
35	Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 647-653.	1.7	113
36	Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic. <i>Mayo Clinic Proceedings</i> , 2010, 85, 225-230.	1.4	113

#	ARTICLE	IF	CITATIONS
37	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	1.7	110
38	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , 2012, 119, 2731-2737.	0.6	108
39	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. <i>European Journal of Haematology</i> , 2018, 101, 237-244.	1.1	107
40	Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. <i>Arthritis and Rheumatism</i> , 2008, 58, 657-666.	6.7	106
41	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2288-2295.	0.8	106
42	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , 2014, 123, 338-345.	0.6	105
43	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. <i>International Journal of Cancer</i> , 2007, 121, 2260-2266.	2.3	104
44	Cancer Incidence among Pesticide Applicators Exposed to Permethrin in the Agricultural Health Study. <i>Environmental Health Perspectives</i> , 2009, 117, 581-586.	2.8	101
45	Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 773-779.	0.8	101
46	Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3069-3075.	1.1	100
47	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1917.	5.8	99
48	New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5428-5433.	3.2	98
49	Minimal residual disease in multiple myeloma: bringing the bench to the bedside. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 286-295.	12.5	97
50	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	1.7	95
51	Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging of early myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1355-1363.	0.6	90
52	Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 2198-2201.	0.6	89
53	Autoimmunity and lymphomagenesis. <i>International Journal of Cancer</i> , 2009, 124, 1497-1502.	2.3	89
54	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	0.6	89

#	ARTICLE	IF	CITATIONS
55	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	1.7	87
56	Different biology and clinical outcome according to the absolute numbers of clonal Bâ€œcells in monoclonal Bâ€œcell lymphocytosis (MBL). <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S19-23.	0.7	86
57	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. <i>Leukemia and Lymphoma</i> , 2013, 54, 2215-2218.	0.6	86
58	Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. <i>Blood</i> , 2013, 122, 1088-1089.	0.6	85
59	MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. <i>Blood Advances</i> , 2017, 1, 728-732.	2.5	84
60	Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. <i>ELife</i> , 2015, 4, e08153.	2.8	84
61	Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia. <i>Journal of the National Cancer Institute</i> , 2010, 102, 557-567.	3.0	83
62	Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. <i>British Journal of Haematology</i> , 2007, 139, 672-686.	1.2	80
63	Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. <i>Haematologica</i> , 2003, 88, 438-44.	1.7	78
64	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e30-e37.	0.2	75
65	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	0.6	74
66	Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. <i>Haematologica</i> , 2009, 94, 1259-1265.	1.7	72
67	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017, 23, 3980-3993.	3.2	71
68	Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. <i>Blood</i> , 2009, 114, 4928-4932.	0.6	70
69	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 478-487.	0.9	69
70	From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention. <i>Clinical Cancer Research</i> , 2011, 17, 1243-1252.	3.2	68
71	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. <i>Nature Communications</i> , 2021, 12, 1861.	5.8	68
72	Risk of Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia Among 120,908 US Veterans With Hepatitis C Virus Infection. <i>Archives of Internal Medicine</i> , 2009, 169, 357.	4.3	67

#	ARTICLE	IF	CITATIONS
73	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1603-1607.	1.7	66
74	Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. <i>American Journal of Hematology</i> , 2013, 88, 60-65.	2.0	66
75	Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. <i>Blood</i> , 2006, 108, 292-296.	0.6	63
76	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , 2009, 125, 2147-2150.	2.3	63
77	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	3.4	63
78	A prospective study of circulating adipokine levels and risk of multiple myeloma. <i>Blood</i> , 2012, 120, 4418-4420.	0.6	58
79	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	3.4	57
80	Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance. <i>JAMA Oncology</i> , 2015, 1, 1061.	3.4	56
81	Risk of Multiple Myeloma following Medication Use and Medical Conditions: A Case-Control Study in Connecticut Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2342-2347.	1.1	55
82	Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 444-449.	1.2	55
83	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. <i>Nature Communications</i> , 2021, 12, 293.	5.8	54
84	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. <i>Seminars in Oncology</i> , 2016, 43, 682-689.	0.8	53
85	Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 791-798.	1.2	52
86	Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 465-480.	1.5	52
87	Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. <i>American Journal of Hematology</i> , 2014, 89, 1159-1160.	2.0	52
88	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. <i>Blood Cancer Journal</i> , 2021, 11, 94.	2.8	52
89	Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. <i>Pharmacotherapy</i> , 2015, 35, 1173-1188.	1.2	51
90	Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. <i>Blood Advances</i> , 2019, 3, 2040-2044.	2.5	50

#	ARTICLE	IF	CITATIONS
91	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	2.2	50
92	Chronic Immune Stimulation and Subsequent Waldenström Macroglobulinemia. <i>Archives of Internal Medicine</i> , 2008, 168, 1903.	4.3	48
93	Multiple Myeloma Precursor Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2397.	3.8	48
94	Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 332-342.	1.1	48
95	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. <i>Blood Advances</i> , 2017, 1, 2186-2192.	2.5	47
96	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
97	Racial Differences in Chronic Immune Stimulatory Conditions and Risk of Non-Hodgkin's Lymphoma in Veterans From the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 378-385.	0.8	45
98	Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years. <i>Haematologica</i> , 2015, 100, 1340-1349.	1.7	43
99	Increased Risk for Lymphoid and Myeloid Neoplasms in Elderly Solid-Organ Transplant Recipients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1229-1237.	1.1	41
100	Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. <i>Blood</i> , 2012, 120, 4929-4937.	0.6	41
101	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. <i>JAMA Oncology</i> , 2020, 6, 425.	3.4	41
102	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	5.8	41
103	Prevalence of monoclonal B-cell lymphocytosis: A systematic review. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S10-8.	0.7	40
104	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 101.	2.8	40
105	Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 904-907.	1.2	40
106	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. <i>Cancer Treatment and Research</i> , 2016, 169, 3-12.	0.2	39
107	Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 1189.	4.3	38
108	Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. <i>American Journal of Hematology</i> , 2011, 86, 475-478.	2.0	38

#	ARTICLE	IF	CITATIONS
109	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
110	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 669-678.	1.2	36
111	Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 2127-2143.	3.3	36
112	Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. <i>Blood</i> , 2007, 110, 4599-4605.	0.6	35
113	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 593-603.	1.5	35
114	Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1523-1532.	2.6	34
115	Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone. <i>JAMA Oncology</i> , 2018, 4, 1781.	3.4	33
116	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 87-97.	0.9	32
117	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. <i>Seminars in Hematology</i> , 2018, 55, 44-50.	1.8	31
118	Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. <i>Haematologica</i> , 2009, 94, 1581-1589.	1.7	30
119	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 15.	2.8	30
120	Biological determinants of health disparities in multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 85.	2.8	29
121	Fractures and survival in multiple myeloma: results from a population-based study. <i>Haematologica</i> , 2020, 105, 1067-1073.	1.7	29
122	Current and future imaging modalities for multiple myeloma and its precursor states. <i>Leukemia and Lymphoma</i> , 2011, 52, 1630-1640.	0.6	27
123	Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and white veterans. <i>Blood</i> , 2006, 108, 1111-1112.	0.6	26
124	Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 19-22.	1.4	25
125	Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 295-302.	0.9	25
126	Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2159-2170.	0.6	25

#	ARTICLE	IF	CITATIONS
127	Shall we treat smoldering multiple myeloma in the near future?. Hematology American Society of Hematology Education Program, 2017, 2017, 194-204.	0.9	25
128	MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. Seminars in Hematology, 2018, 55, 1-3.	1.8	25
129	Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. British Journal of Haematology, 2007, 139, 717-723.	1.2	24
130	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS ONE, 2019, 14, e0211600.	1.1	24
131	Molecular Imaging in Myeloma Precursor Disease. Seminars in Hematology, 2011, 48, 22-31.	1.8	23
132	MGUS prevalence in an ethnically Chinese population in Hong Kong. Blood, 2013, 121, 2363-2364.	0.6	23
133	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leukemia and Lymphoma, 2016, 57, 1114-1121.	0.6	23
134	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. American Journal of Hematology, 2019, 94, 1364-1373.	2.0	22
135	Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma. Journal of Molecular Diagnostics, 2020, 22, 901-911.	1.2	22
136	Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncology, 2021, 7, 132.	3.4	21
137	Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry Part B - Clinical Cytometry, 2010, 78B, S91-7.	0.7	20
138	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Annals of Hematology, 2017, 96, 261-269.	0.8	20
139	Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clinical Cancer Research, 2021, 27, 15-23.	3.2	20
140	Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE, 2018, 13, e0206047.	1.1	19
141	Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. Advances in Cell and Gene Therapy, 2019, 2, e26.	0.6	19
142	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	1.2	19
143	Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 248-257.	0.2	18
144	Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. American Journal of Hematology, 2016, 91, E502-E503.	2.0	18

#	ARTICLE	IF	CITATIONS
145	Comorbidities in multiple myeloma and implications on survival: A population-based study. <i>European Journal of Haematology</i> , 2021, 106, 774-782.	1.1	18
146	Pursuing the curative blueprint for early myeloma. <i>Blood</i> , 2013, 122, 486-490.	0.6	17
147	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. <i>Obesity</i> , 2017, 25, 1317-1320.	1.5	17
148	Genetics- and Immune-Related Factors in the Pathogenesis of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 23-26.	1.4	16
149	Host-related immunodeficiency in the development of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1127-1132.	0.6	16
150	Evolving therapeutic paradigms for multiple myeloma: back to the future. <i>Leukemia and Lymphoma</i> , 2013, 54, 451-463.	0.6	15
151	Common community-acquired infections and subsequent risk of multiple myeloma: A population-based study. <i>International Journal of Cancer</i> , 2014, 134, 1734-1740.	2.3	15
152	Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. <i>Environmental Health Perspectives</i> , 2021, 129, 17003.	2.8	15
153	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 67-76.	2.3	14
154	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. <i>Seminars in Hematology</i> , 2011, 48, 46-54.	1.8	13
155	Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1445-1449.	1.3	12
156	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. <i>Pathology</i> , 2021, 53, 385-399.	0.3	12
157	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1678.	3.4	12
158	Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas. <i>European Journal of Clinical & Medical Oncology</i> , 2010, 2, 119-126.	0.0	12
159	Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology. <i>European Journal of Radiology</i> , 2014, 83, 970-974.	1.2	11
160	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e493-e503.	1.8	11
161	Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2017, 58, 639-645.	0.6	11
162	Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 662-672.	0.9	11

#	ARTICLE	IF	CITATIONS
163	What Causes Waldenström's Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 85-87.	0.2	10
164	High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. <i>American Journal of Hematology</i> , 2011, 86, 554-558.	2.0	10
165	Etiology of Waldenström Macroglobulinemia: Genetic Factors and Immune-related Conditions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 194-197.	0.2	10
166	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz104.	1.4	10
167	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e213-e220.	0.2	9
168	Antibody Response to Pneumococcal Polysaccharide Vaccination Predicts Pneumococcal Disease in Splenectomized Patients with Hematological Diseases.. <i>Blood</i> , 2004, 104, 1335-1335.	0.6	9
169	Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities. <i>Seminars in Hematology</i> , 2011, 48, 1-3.	1.8	8
170	Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. <i>British Journal of Haematology</i> , 2012, 157, 125-127.	1.2	8
171	Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 187-190.	0.2	8
172	Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. <i>Modern Pathology</i> , 2018, 31, 881-889.	2.9	8
173	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 58-65.	2.0	8
174	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8
175	Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 559-568.	0.3	8
176	Monoclonal B cell lymphocytosis: Clinical and population perspectives. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S115-9.	0.7	7
177	Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. <i>Seminars in Hematology</i> , 2011, 48, 66-72.	1.8	7
178	Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. <i>American Journal of Hematology</i> , 2013, 88, 89-92.	2.0	7
179	Proteomic profiling in plasma cell disorders: a feasibility study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1757-1759.	0.6	7
180	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141.	0.5	7

#	ARTICLE	IF	CITATIONS
181	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 191.	2.8	7
182	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	1.1	6
183	Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 187-193.	0.7	5
184	A phase 1b study of once-a-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 226-233.	2.0	5
185	Modern Myeloma Therapy + Sustained Minimal Residual Disease = (Functional) Cure!. <i>Journal of Clinical Oncology</i> , 2022, 40, 2863-2866.	0.8	5
186	Thromboprophylaxis in multiple myeloma: is the evidence there?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 291-294.	1.1	4
187	Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2020, 83, 269-278.	1.1	4
188	Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 473-478.	1.0	3
189	Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. <i>Blood</i> , 2009, 114, 2356-2357.	0.6	3
190	Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. <i>Haematologica</i> , 2014, 99, 1769-1771.	1.7	3
191	No CLL transmission through blood transfusion. <i>Blood</i> , 2015, 126, 1978-1979.	0.6	3
192	Myeloma imaging: time to move on!. <i>Leukemia and Lymphoma</i> , 2016, 57, 1499-1500.	0.6	3
193	Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 217-221.	1.1	3
194	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. <i>Scientific Reports</i> , 2019, 9, 14884.	1.6	3
195	The Road to Treating Smoldering Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S59-S64.	0.2	2
196	Racial/ethnic disparities: need more work!. <i>Blood</i> , 2017, 130, 1685-1686.	0.6	2
197	Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. <i>European Journal of Haematology</i> , 2021, 107, 137-144.	1.1	2
198	Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>Blood Cancer Journal</i> , 2022, 12, 51.	2.8	2

#	ARTICLE	IF	CITATIONS
199	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.	3.2	2
200	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance—reply—. <i>Mayo Clinic Proceedings</i> , 2008, 83, 602-603.	1.4	1
201	Evolution of a precursor. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 1-3.	0.7	1
202	Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status. <i>Seminars in Oncology</i> , 2016, 43, 703-706.	0.8	1
203	Epidemiology of Waldenström Macroglobulinemia. , 2017, , 97-109.		1
204	Epidemiology and Pathophysiology of Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018, , 1-15.	0.2	1
205	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions. <i>Seminars in Oncology</i> , 2022, , .	0.8	1
206	Parental longevity and survival in elderly patients with Hodgkin's lymphoma. <i>Haematologica</i> , 2002, 87, 596-601.	1.7	1
207	Diagnosed with myeloma before age 40. <i>Blood</i> , 2021, 138, 2601-2602.	0.6	1
208	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2760-2761.	0.6	1
209	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance—reply—. <i>Mayo Clinic Proceedings</i> , 2008, 83, 602-603.	1.4	0
210	A Case Study Progression to Multiple Myeloma. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 419-422.	0.3	0
211	Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma. <i>Current Radiology Reports</i> , 2016, 4, 1.	0.4	0
212	Serum protein markers of clonal heterogeneity in myeloma. <i>Lancet Haematology</i> , the, 2017, 4, e565-e566.	2.2	0
213	Monoclonal Gammopathy of Undetermined Significance. , 2018, , 525-530.		0
214	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>British Journal of Haematology</i> , 2019, 186, 37-44.	1.2	0
215	Future prospects of chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e72.	0.6	0
216	Familial patterns of hematologic precursors. <i>Blood</i> , 2021, 137, 1992-1993.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Response to Splenectomy Is Durable after a Certain Point in Time in Adult ITP Patients.. Blood, 2005, 106, 3976-3976.	0.6	0
218	Title is missing!. , 2017, , .		0